Alexa

Vaccine for uterine cancer seen as more effective on pre-teens

子宮頸癌疫苗於青春期前注射較有效

Vaccine for uterine cancer seen as more effective on pre-teens

An experimental vaccine developed by Glaxo Smith Kline that targets two viruses

responsible for 70 percent of uterine cancer cases triggers twice the immune

response in girls aged 10 to 14 than in those aged 15 to 24, the British

pharmaceutical firm said yesterday.

英國藥廠指出,在一項由葛蘭素史克藥廠針對兩種子宮頸癌病毒(百分之七十子宮頸癌都是

由這兩種病毒所造成)所研發的實驗性疫苗,十歲至十四歲的少女產生的免疫反應,是十五

到二十四歲少女的兩倍。

The results of phase 3 clinical trials were presented at an annual conference

on infectious diseases under way this weekend in Washington.

這項臨床實驗進行到第三階段,實驗結果這個週末發表於華盛頓的年度傳染病會議上。

They indicate that the vaccine Cervarix could offer more durable and efficient

protection, if it is given to the young, well ahead of their becoming sexually

active.

他們表示如果讓年輕少女開始有性行為之前,注射這個名為Cervarix的疫苗,能夠提供她們

更持久且有效的保護。

"Vaccination of pre-teen/adolescent girls against cancer-causing HPV (Human

Papillomavirus) before onset of sexual activity will be an important part of

the overall strategy for cervical cancer prevention," said Anna-Barbara

Moscicki, a pediatrics professor from the University of California.

加州大學的小兒科教授安娜.芭芭拉.莫斯契基表示:「讓青春期以前與青春期的女在開始

有性行為之前,注射此種抗人類乳突病毒(HPV)的疫苗,在子宮頸癌的防治方法上,是很重

要的。」

The two viruses are responsible for 70 percent of cases of uterine cancer. More

than 500,000 cases of this disease are diagnosed in the world each year.

有百分之七十的子宮頸癌病例由這兩種病毒造成。全世界每年有五十萬以上被診斷為此種疾

病。


Updated : 2021-03-07 14:33 GMT+08:00